Iovance Biotherapeutics, Inc.
8.43USD
-0.2700 (-3.10%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.1▲ | $-0.12 | 6 | 0 |
| Next quarter | $-0.11▲ | $-0.12 | 5 | 1 |
| Current year | $-0.5▲ | $-0.56 | 6 | 0 |
| Next year | $-0.29▲ | $-0.32 | 5 | 2 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.13 | $-0.11 | +0.02 (+18.4%) |
| 2026-03-31 | $-0.15 | $-0.19 | -0.04 (-23.8%) |
| 2025-12-31 | $-0.18 | $-0.18 | -0.00 (-2.1%) |
| 2025-09-30 | $-0.26 | $-0.25 | +0.01 (+2.8%) |
152 ratings from 18 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| TD Cowen | Maintained | Buy | $7 $10 | Aug 25, 2026 |
| UBS | Maintained | Neutral | $4 $7 | Aug 20, 2026 |
| Mizuho | Maintained | Outperform | $10 $11 | Aug 18, 2026 |
| Barclays | Maintained | Overweight | $11 $13 | Aug 7, 2026 |
| Citizens | Maintained | Market Outperform | $5 $8 | Aug 7, 2026 |
| Chardan Capital | Maintained | Buy | $16 $14 | May 8, 2026 |
| Chardan Capital | Maintained | Buy | $16 | Apr 10, 2026 |
| UBS | Maintained | Neutral | $2 $4 | Mar 5, 2026 |
| Citizens | Upgraded from Market Perform | Market Outperform | $5 | Mar 3, 2026 |
| Barclays | Maintained | Overweight | $10 $11 | Feb 25, 2026 |
| Citizens | Upgraded from Market Perform | Market Outperform | $5 | Feb 25, 2026 |
| Barclays | Maintained | Overweight | $9 $10 | Dec 17, 2025 |
| Barclays | Maintained | Overweight | $4 $9 | Nov 24, 2025 |
| Chardan Capital | Maintained | Buy | $20 $17 | Nov 6, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $20 $9 | Oct 29, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $20 | Aug 19, 2025 |
| Wells Fargo | Maintained | Overweight | $18 $14 | Aug 8, 2025 |
| Chardan Capital | Maintained | Buy | $25 $20 | Aug 8, 2025 |
| Chardan Capital | Maintained | Buy | $25 | Jul 23, 2025 |
| UBS | Downgraded from Buy | Neutral | $17 $2 | May 16, 2025 |
| Goldman Sachs | Maintained | Buy | $16 $8 | May 12, 2025 |
| Mizuho | Maintained | Outperform | $30 $10 | May 12, 2025 |
| Barclays | Maintained | Overweight | $5 $4 | May 12, 2025 |
| JMP Securities | Downgraded from Market Outperform | Market Perform | — | May 9, 2025 |
| Chardan Capital | Maintained | Buy | $30 $25 | May 9, 2025 |
68 filings from 11 insiders · 0 buy / 0 sell over 6m
Officers and directors of IOVA, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Vogt Frederick GDirector; Officer, Interim CEO & General Counsel | ExerciseRestricted Stock Units | 41.7k | — | — | Sep 1, 2026 |
| Vogt Frederick GDirector; Officer, Interim CEO & General Counsel | Tax | 17.7k | $8.28 | $147k | Sep 1, 2026 |
| Vogt Frederick GDirector; Officer, Interim CEO & General Counsel | Exercise | 41.7k | — | — | Sep 1, 2026 |
| Puri Raj K.Officer, Chief Regulatory Officer | ExerciseRestricted Stock Units | 5.5k | — | — | Sep 1, 2026 |
| Puri Raj K.Officer, Chief Regulatory Officer | Tax | 2.5k | $8.28 | $21k | Sep 1, 2026 |
| Puri Raj K.Officer, Chief Regulatory Officer | Exercise | 5.5k | — | — | Sep 1, 2026 |
| BILINSKY IGOROfficer, Chief Operating Officer | ExerciseRestricted Stock Units | 8.8k | — | — | Sep 1, 2026 |
| BILINSKY IGOROfficer, Chief Operating Officer | Tax | 4.5k | $8.28 | $37k | Sep 1, 2026 |
| BILINSKY IGOROfficer, Chief Operating Officer | Exercise | 8.8k | — | — | Sep 1, 2026 |
| KIRBY DANIEL GORDONOfficer | Other | 10.0k | — | — | Aug 10, 2026 |
| ROCHE CORLEEN MChief Financial Officer | Other | 50.0k | — | — | Aug 6, 2026 |
| GRAF FINCKENSTEIN FRIEDRICHOfficer | Other | 7.8k | — | — | Jun 5, 2026 |
| PURI RAJ KOfficer | Other | 9.8k | — | — | Jun 5, 2026 |
| BILINSKY IGOR PChief Operating Officer | Other | 7.8k | — | — | Jun 5, 2026 |
| VOGT FREDERICK GChief Executive Officer | Other | 15.6k | — | — | Jun 5, 2026 |
| GRAF FINCKENSTEIN FRIEDRICHOfficer | Other | 8.8k | — | — | Jun 1, 2026 |
| PURI RAJ KOfficer | Other | 5.5k | — | — | Jun 1, 2026 |
| BILINSKY IGOR PChief Operating Officer | Other | 8.8k | — | — | Jun 1, 2026 |
| VOGT FREDERICK GChief Executive Officer | Other | 41.7k | — | — | Jun 1, 2026 |
| KIRBY DANIEL GORDONOfficer | Other | 10.0k | — | — | May 11, 2026 |
No analyst notes on IOVA yet.
Analyst Ratings
9 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 5 | 2 | 0 | 0 | Buy2.00 |
| 1 mo ago | 2 | 5 | 2 | 0 | 0 | Buy2.00 |
| 2 mo ago | 2 | 6 | 2 | 0 | 0 | Buy2.00 |